Monday, April 29, 2019
23andMe Misses Almost 90% of BRCA Mutation Carriers
Although 23andMe was not mentioned by name in the results, presented at the annual American College of Medical Genetics and Genomics recently, the study criticizes the lack of clinical utility of direct-to-consumer tests rather than criticizing the company itself.
Apparently 23andMe has been widely criticized for offering the test which gives many women a false sense of security. The FDA does caution women being tested by 23andMe that over 1,000 other BRCA mutations are not tested. That's a shockingly high number.
Of 4,700 women tested by another company, Invitae, only 12% had one of the 3 mutations tested for by 23andMe; 88% had a different mutation.
I understand why women with a personal history of breast or ovarian cancer choose to be tested by 23andMe - it's much cheaper when paying out of pocket for something their own insurance may not cover. These results should strengthen arguments to insurance companies to fully cover genetic testing.
To read the complete article, follow this link.
Friday, April 19, 2019
Immunotherapy and Gynecological Cancers from Facebook Live
Thanks to Anne for sending this link along to me.
Ursula Matulonis, M.D. and director of GynOnc at Dana Farber, has recently presented new information on Facebook Live about immunotherapy for ovarian cancer.
She discusses research advances, clinical trials, and the buzz that surrounds gynecological immunotherapy.
Thursday, April 4, 2019
Cruise for a Cause: Saturday May 4, 2019
Tuesday, April 2, 2019
CD47: The "Don't Eat Me" Signal
So why do cancer cells evade macrophages? That's what researchers are working on finding the answers to. But one group, out of Stanford, have discovered one escape mechanism that cancer cells use to evade macrophages.
Called CD47, this protein coats cancer cells and sends out a "don't eat me" signal. It is very commonly expressed in the body (after all, we don't want macrophages to eat good cells). How cancer cells hijack CD47 to protect itself is a mystery but researchers have found a way to block CD47 on cancer cells in a phase 1 study. Altho phase 1 studies are designed to determine the overall safety of a drug as well as optimal dosing, several women with ovarian or fallopian malignancies had partial remissions of their disease. This has prompted phase 2 trials to begin for ovarian cancer.
To read more about this research, follow this link.
Subscribe to: Posts (Atom)